Cargando…
Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma
BACKGROUND: Pemigatinib is an inhibitor of the fibroblast growth factor receptor (FGFR), recently approved for the treatment of cholangiocarcinoma. FGFR retinopathy is a newly recognized entity, with only two other FGFR inhibitors reported to cause serous retinopathy. Herein, we describe the first p...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067404/ https://www.ncbi.nlm.nih.gov/pubmed/33892812 http://dx.doi.org/10.1186/s40942-021-00305-9 |